Townsquare Capital LLC Sells 5,145 Shares of Gilead Sciences, Inc. $GILD

Townsquare Capital LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,151 shares of the biopharmaceutical company’s stock after selling 5,145 shares during the period. Townsquare Capital LLC’s holdings in Gilead Sciences were worth $794,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Argent Advisors Inc. raised its stake in Gilead Sciences by 7.4% during the 3rd quarter. Argent Advisors Inc. now owns 11,622 shares of the biopharmaceutical company’s stock worth $1,290,000 after acquiring an additional 798 shares during the period. Knights of Columbus Asset Advisors LLC boosted its position in shares of Gilead Sciences by 94.4% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 56,123 shares of the biopharmaceutical company’s stock worth $6,230,000 after purchasing an additional 27,260 shares during the period. Impact Partnership Wealth LLC increased its stake in shares of Gilead Sciences by 22.9% in the third quarter. Impact Partnership Wealth LLC now owns 16,151 shares of the biopharmaceutical company’s stock worth $1,793,000 after purchasing an additional 3,013 shares in the last quarter. MTM Investment Management LLC raised its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the period. Finally, Patton Albertson Miller Group LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $828,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GILD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Daiwa Capital Markets lifted their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. UBS Group boosted their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Morgan Stanley lowered their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $136.36.

Gilead Sciences Trading Up 1.7%

GILD stock opened at $141.95 on Friday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $142.20. The stock has a market capitalization of $176.11 billion, a price-to-earnings ratio of 22.01, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm’s fifty day simple moving average is $125.36 and its two-hundred day simple moving average is $119.59.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 257,397 shares of company stock valued at $33,385,512 over the last quarter. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.